Blocking a protein in the cervix to create a new type of birth control
Inhibiting the cystic fibrosis transmembrane conductance regulator (CFTR) in the cervix as a novel approach to non-hormonal contraception
This study is exploring a new way to prevent pregnancy by using a method that keeps cervical mucus thicker during ovulation, which could stop sperm from reaching the uterus, and it’s designed for anyone looking for a non-hormonal birth control option.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11017071 on NIH RePORTER |
What this research studies
This research investigates a non-hormonal method of contraception by inhibiting a protein called CFTR in the cervix, which affects the consistency of cervical mucus. The study aims to prevent the mucus from becoming too fluid during ovulation, which allows sperm to enter the uterus. By maintaining a thicker mucus consistency, this approach could provide an effective contraceptive method without altering the menstrual cycle. The research will involve laboratory studies to understand how this inhibition works and its potential effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are women who experience cervical factor infertility or are seeking non-hormonal contraceptive methods.
Not a fit: Patients who are not seeking contraception or have no issues related to cervical mucus quality may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new form of contraception that does not rely on hormones, offering more options for women.
How similar studies have performed: While the approach of targeting CFTR in the cervix is novel, similar strategies in reproductive health have shown promise in other contexts.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Han, Leo Liu — Oregon Health & Science University
- Study coordinator: Han, Leo Liu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.